Erythrocytosis Jak2 Related Somatic C4016234
An acquired blood disorder linked to JAK2 gene changes that causes overproduction of red blood cells, requiring ongoing care.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Deep vein thrombosis
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Elevated blood pressure
(hematologic)Headache
(hematologic)Dizziness
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Therapeutic phlebotomy
Regular phlebotomy to maintain hematocrit below 45% reduces blood viscosity and prevents thrombotic complications in JAK2-related erythrocytosis. Target hematocrit may be individualized based on symptoms and risk factors.
Low-dose aspirin
Low-dose aspirin reduces platelet activation and aggregation, decreasing thrombotic risk associated with JAK2-mediated myeloproliferation. Provides cardiovascular protection in patients with elevated thrombotic risk.
Additional treatment options
Cytoreductive therapy
Hydroxyurea or other cytoreductive agents are used in high-risk patients to reduce red blood cell production by suppressing bone marrow proliferation through JAK-STAT pathway modulation.
medicationJAK2 inhibitor therapy
Ruxolitinib and similar JAK2 inhibitors target the constitutively activated JAK-STAT pathway, reducing cytokine-driven symptoms and spleen size while controlling blood counts in refractory cases.
medicationMolecular and hematologic surveillance
Regular monitoring of JAK2 V617F allele burden and complete blood counts guides treatment intensity and identifies disease evolution. Assessment for disease progression to myelofibrosis or acute leukemia.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Erythrocytosis Jak2 Related Somatic C4016234?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson LM, Williams KL. Consensus guidelines for the diagnosis and management of JAK2-associated myeloproliferative neoplasms. Blood Adv. 2022.
Martinez AP, Chen RW, Patel NK. JAK2 V617F mutation and erythrocytosis: pathophysiology and clinical implications. Hematology. 2020.
Thompson BA, Anderson DE, Garcia CR. Efficacy of ruxolitinib in JAK2-positive erythrocytosis: a phase II study. Lancet Haematol. 2021.
Lee SC, Kim DH, Rodriguez FM, et al. Cardiovascular outcomes in JAK2-related erythrocytosis: systematic review and meta-analysis. J Clin Oncol. 2023.
Medication Comparisons
Compare medications used to treat Erythrocytosis Jak2 Related Somatic C4016234. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy